- Home
- DAVE vs VKTX Comparison
DAVE vs VKTX Comparison
Compare DAVE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- VKTX
- Stock Information
- Founded
- DAVE 2017
- VKTX 2012
- Country
- DAVE United States
- VKTX United States
- Employees
- DAVE N/A
- VKTX N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- VKTX Health Care
- Exchange
- DAVE Nasdaq
- VKTX Nasdaq
- Market Cap
- DAVE 3.1B
- VKTX 2.8B
- IPO Year
- DAVE N/A
- VKTX 2015
- Fundamental
- Price
- DAVE $211.00
- VKTX $26.01
- Analyst Decision
- DAVE Strong Buy
- VKTX Buy
- Analyst Count
- DAVE 6
- VKTX 12
- Target Price
- DAVE $212.33
- VKTX $84.00
- AVG Volume (30 Days)
- DAVE 440.1K
- VKTX 2.9M
- Earning Date
- DAVE 08-04-2025
- VKTX 07-23-2025
- Dividend Yield
- DAVE N/A
- VKTX N/A
- EPS Growth
- DAVE N/A
- VKTX N/A
- EPS
- DAVE 3.70
- VKTX N/A
- Revenue
- DAVE $381,425,000.00
- VKTX N/A
- Revenue This Year
- DAVE $37.77
- VKTX N/A
- Revenue Next Year
- DAVE $17.77
- VKTX N/A
- P/E Ratio
- DAVE $57.24
- VKTX N/A
- Revenue Growth
- DAVE 39.31
- VKTX N/A
- 52 Week Low
- DAVE $28.31
- VKTX $18.92
- 52 Week High
- DAVE $243.25
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- DAVE 57.19
- VKTX 44.01
- Support Level
- DAVE $186.20
- VKTX $25.61
- Resistance Level
- DAVE $243.25
- VKTX $30.17
- Average True Range (ATR)
- DAVE 13.35
- VKTX 1.43
- MACD
- DAVE -5.24
- VKTX -0.21
- Stochastic Oscillator
- DAVE 43.47
- VKTX 9.76
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.